Global Recombinant Proteins Market

Report Highlights

The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.

Report Includes

• 45 data tables and 46 additional tables
• Analysis of the global market for recombinant proteins
• Analyses of the global market trends, with market revenue data for 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
• Discussion of the market drivers, restraints and opportunities
• Estimate of the current market size and revenue prospects, along with a market share analysis by product (protein type), host cell type, application and region
• Facts and figures pertaining to the market dynamics, current and emerging technologies, regulatory scenario, and the expected impact of macroeconomic factors
• Overview of sustainability and ESG trends, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices
• Analysis of recent patents and pipeline activity
• A look at the industry structure, including companies’ market shares, M&A activity and venture funding
• Company profiles of major players within the industry, including Novo Nordisk A/S, Lilly, Sanofi, and Amgen Inc.

Report Scope

This report covers the current and future global market for recombinant proteins, including a detailed analysis of the market’s drivers, restraints and opportunities. The report also covers market projections for 2029, the market’s competitive environment and companies’ pipeline activities. The report delivers market estimates and forecasts for recombinant proteins categorized according to product type, host cell type, application, and region. Based on product type the market is segmented into hormones, cytokines, enzymes, antigens, antibodies, and others. Based on the host cell type, recombinant proteins are categorized as mammalian, insect, yeast and fungi, bacterial, and other cell types. The market is segmented by application into therapeutics and vaccines, biomedical research, and diagnostics. The report includes the company profiles of the key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report does not cover proteins produced through hybridoma techniques. The report also excludes COVID-19 vaccines based on recombinant technology.

By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Regional analysis is further broken down by country as follows: North America—the U.S. and Canada; Europe—Germany, the U.K., France, Italy, and the Rest of Europe; Asia-Pacific—China, Japan, India, and the Rest of Asia-Pacific. For market estimates, data have been provided for 2021 and 2022 as the historic years, 2023 as the base year, and a forecast through 2029.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.